SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Dec 19, 2017
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Dec. 19, 2017 · CIK: 0001513525 · Accession: 0001213900-17-013403
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220368
Letter
Adial Pharmaceuticals, Inc.
Seminole Trail, Suite 495
Charlottesville, VA 22901
December 19, 2017
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Suzanne Hayes
Re: Adial Pharmaceuticals, Inc.
Withdrawal of Acceleration Request
Registration Statement on Form S-1 (as amended)
File No: 333-220368
Ladies and Gentlemen:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests withdrawal of its acceleration request letter filed as correspondence via EDGAR on December 15, 2017, which requested that the above-referenced Registration Statement on Form S-1 (File No. 333-220368) become effective on Tuesday, December 19, 2017, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable. The Registrant is no longer requesting that such Registration Statement be declared effective at this time and the Registrant hereby formally withdraws its request for acceleration of the effective date.
If you have any questions regarding the foregoing, please contact our counsel, Leslie Marlow of Gracin & Marlow, LLP, at (516) 496-2223 or (212) 907-6457.
Very truly
yours,
Adial
Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Adial
Pharmaceuticals, Inc.
1180
Seminole Trail, Suite 495
Charlottesville, VA 22901
December
19, 2017
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington,
D.C. 20549
Attention: Ms. Suzanne Hayes
Re:
Adial
Pharmaceuticals, Inc.
Withdrawal
of Acceleration Request
Registration
Statement on Form S-1 (as amended)
File
No: 333-220368
Ladies
and Gentlemen:
Adial
Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests withdrawal of its acceleration request
letter filed as correspondence via EDGAR on December 15, 2017, which requested that the above-referenced Registration Statement
on Form S-1 (File No. 333-220368) become effective on Tuesday, December 19, 2017, at 5:00 p.m., Eastern Time, or as soon thereafter
as is practicable. The Registrant is no longer requesting that such Registration Statement be declared effective at this time
and the Registrant hereby formally withdraws its request for acceleration of the effective date.
If
you have any questions regarding the foregoing, please contact our counsel, Leslie Marlow of Gracin & Marlow, LLP, at (516)
496-2223 or (212) 907-6457.
Very truly
yours,
Adial
Pharmaceuticals, Inc.
By: /s/
William B. Stilley
Name:
William
B. Stilley
Title:
Chief
Executive Officer
cc:
Joseph
Truluck, Chief Financial Officer of Adial Pharmaceuticals, Inc.
Leslie
Marlow, Esq., Gracin & Marlow, LLP